Abstract
Alzheimer's disease (AD) is a multifactorial syndrome with several target proteins contributing to its etiology. To confront AD, an innovative strategy is to design single chemical entities able to simultaneously modulate more than one target. Here, we present compounds that inhibit acetylcholinesterase and NMDA receptor activity. Furthermore, these compounds inhibit AChE-induced Abeta aggregation and display antioxidant properties, emerging as lead candidates for treating AD.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Acetylcholinesterase / chemistry
-
Acetylcholinesterase / metabolism*
-
Alzheimer Disease / metabolism*
-
Amyloid / antagonists & inhibitors*
-
Amyloid / metabolism
-
Cholinesterase Inhibitors / chemical synthesis*
-
Cholinesterase Inhibitors / chemistry
-
Cholinesterase Inhibitors / pharmacology*
-
Humans
-
Inhibitory Concentration 50
-
Ligands
-
Models, Molecular
-
Molecular Structure
-
Protein Binding
-
Receptors, N-Methyl-D-Aspartate / antagonists & inhibitors*
-
Receptors, N-Methyl-D-Aspartate / metabolism
-
Structure-Activity Relationship
Substances
-
Amyloid
-
Cholinesterase Inhibitors
-
Ligands
-
Receptors, N-Methyl-D-Aspartate
-
Acetylcholinesterase